Influence of METHoxyflurane on ANtiplatelet Effect of Ticagrelor in Patients With Unstable Angina Pectoris

Korábbi kezelés

• Treatment with ticlopidine, clopidogrel, prasugrel or ticagrelor within 14 days before the study enrollment
• Current treatment with morphine or any opioid "mi" receptor agonist
• Current treatment with oral anticoagulant or chronic therapy with low-molecular-weight heparin
• Concomitant therapy with strong CYP3A inhibitors (ketoconazole, itraconazole, voriconazole, telithromycin, clarithromycin, nefazadone, ritonavir, saquinavir, nelfinavir, indinavir, atazanavir) or strong CYP3A inducers (rifampicin, phenytoin, carbamazepine, dexamethasone, phenobarbital) within 14 days and during study treatment

Más betegség

• Hypersensitivity to ticagrelor
• Active bleeding
• History of intracranial hemorrhage
• Recent gastrointestinal bleeding (within 30 days)
• History of coagulation disorders
• History of moderate or severe hepatic impairment
• History of major surgery or severe trauma (within 3 months)
• History of asthma or severe chronic obstructive pulmonary disease
• Kidney disease requiring dialysis
• Manifest infection or inflammatory state
• Respiratory failure
• History of severe chronic heart failure (NYHA class III or IV)

Laborértékek

• Platelet count less than \<100 x10\^3/mcl
• Hemoglobin concentration less than 10.0 g/dl

Egyéb

• Risk of bradycardic events as judged by the investigator
• Second- or third-degree atrioventricular block during screening for eligibility
• Killip class III or IV during screening for eligibility
• Body weight below 50 kg

• Provision of informed consent prior to any study specific procedures
• Diagnosis of unstable angina
• Male or non-pregnant female, aged 18-80 years
• Provision of informed consent for angiography and PCI
• GRACE score \<140 pts